Reimbursement of Travel and Subsistence Expenses Toward Living Organ Donation Eligibility Guidelines, 11930 [E8-4185]
Download as PDF
<![CDATA[
11930
Federal Register / Vol. 73, No. 44 / Wednesday, March 5, 2008 / Notices
Dated: February 28, 2008.
Alexandra Huttinger,
Director, Division of Policy Review and
Coordination.
[FR Doc. E8–4269 Filed 3–4–08; 8:45 am]
BILLING CODE 4165–15–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Health Resources and Services
Administration
Reimbursement of Travel and
Subsistence Expenses Toward Living
Organ Donation Eligibility Guidelines
Health Resources and Services
Administration, HHS.
ACTION: Request for Comments on
Proposed Changes to the
Reimbursement of Travel and
Subsistence Expenses Program
Eligibility Criteria.
jlentini on PROD1PC65 with NOTICES
AGENCY:
SUMMARY: The Health Resources and
Services Administration (HRSA)
published the final eligibility guidelines
for the Reimbursement of Travel and
Subsistence Expense Program in the
Federal Register on October 5, 2007 (72
FR 57049). The purpose of this notice
was to inform the public of the
eligibility requirements for participation
in the Reimbursement of Travel and
Subsistence Expenses toward Living
Organ Donation Program. HRSA is
requesting public comments concerning
recommended change to a specific
section of the reimbursement program
eligibility guidelines.
DATES: Written comments must be
submitted to the office in the address
section below by mail or e-mail on or
before April 4, 2008.
ADDRESSES: Please send all written
comments to James F. Burdick, M.D.,
Director, Division of Transplantation,
Healthcare Systems Bureau, Health
Resources and Services Administration,
Room 12C–06, Parklawn Building, 5600
Fishers Lane, Rockville, Maryland
20857; telephone (301) 443–7577; fax
(301) 594–6095; or e-mail:
jburdick@hrsa.gov.
FOR FURTHER INFORMATION CONTACT:
James F. Burdick, M.D., Director,
Division of Transplantation, Healthcare
Systems Bureau, Health Resources and
Services Administration, Parklawn
Building, Room 12C–06, 5600 Fishers
Lane, Rockville, Maryland 20857;
telephone (301) 443–7577; fax (301)
594–6095; or e-mail: jburdick@hrsa.gov.
SUPPLEMENTARY INFORMATION: In its final
program eligibility guidelines, HRSA
explained that ‘‘[t]he Program will pay
for a total of up to five trips; three for
VerDate Aug<31>2005
18:03 Mar 04, 2008
Jkt 214001
the donor and two for accompanying
persons. The accompanying persons
need not be the same each trip.’’ (72 FR
57052). HRSA proposes amending this
paragraph to read: ‘‘[t]he Program will
pay for a total of up to five trips; three
for the donor and two for accompanying
persons. However, in cases in which the
transplant center requests the donor to
return to the transplant center for
additional visits as a result of donor
complications or other health related
issues, NLDAC may provide
reimbursement for the additional visit(s)
for the donor and an accompanying
person. The accompanying persons
need not be the same in each trip.’’ The
purpose of this proposed change is to
accommodate individuals who
experience donor complications or other
health related issues relating to
donation.
HRSA is requesting comments on this
specific section.
Dated: February 26, 2008.
Elizabeth M. Duke,
Administrator.
[FR Doc. E8–4185 Filed 3–4–08; 8:45 am]
BILLING CODE 4165–15–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
Government-Owned Inventions;
Availability for Licensing
National Institutes of Health,
Public Health Service, HHS.
AGENCY:
ACTION:
Notice.
SUMMARY: The inventions listed below
are owned by an agency of the U.S.
Government and are available for
licensing in the U.S. in accordance with
35 U.S.C. 207 to achieve expeditious
commercialization of results of
federally-funded research and
development. Foreign patent
applications are filed on selected
inventions to extend market coverage
for companies and may also be available
for licensing.
Licensing information and
copies of the U.S. patent applications
listed below may be obtained by writing
to the indicated licensing contact at the
Office of Technology Transfer, National
Institutes of Health, 6011 Executive
Boulevard, Suite 325, Rockville,
Maryland 20852–3804; telephone: 301/
496–7057; fax: 301/402–0220. A signed
Confidential Disclosure Agreement will
be required to receive copies of the
patent applications.
ADDRESSES:
PO 00000
Frm 00072
Fmt 4703
Sfmt 4703
PSM Peptides as Vaccine Targets
Against Methicillin-Resistant
Staphylococcus aureus
Description of Technology: Available
for licensing and commercial
development are compositions and
methods for the treatment and
inhibition of Methicillin-resistant
Staphylococcus aureus (MRSA), a
dangerous human pathogen. The
invention concerns immunogenic
peptides that can be used to induce
protective immunity against MRSA,
including phenol-soluble modulin
(PSM) peptides.
In addition to the MRSA infections
that occur in immunocompromised
patients in hospitals, new MRSA strains
have recently emerged that can cause
severe infections (such as necrotizing
fasciitis) or death in otherwise healthy
adults. These strains are increasingly
involved in community-associated
(CA)–MRSA infections, and can be
contracted outside of the health care
settings. The incidence of CA–MRSA
infections is increasing and the majority
of infections in patients reporting to
emergency departments in the U.S. is
now due to CA–MRSA.
The invention describes a class of
secreted staphylococcal peptides with
an extraordinary ability to recruit,
activate, and subsequently lyse human
neutrophils, thus eliminating the main
cellular defense against S. aureus
infection. The peptides are encoded by
the PSM gene cluster and include
PSMa1, PSMa2, PSMa3, and PSMa4,
all of which activate and subsequently
lyse neutrophils. These peptides are
produced at especially high levels in
CA–MRSA and to a large extent
determine their aggressive behavior and
ability to cause disease in animal
models of infection. Thus, the peptides
represent a set of virulence factors of S.
aureus that account for the enhanced
virulence of CA–MRSA. The
identification of these peptides enables
the production of vaccines and other
preventative and/or therapeutic agents
for use in subjects infected with MRSA.
Applications: Development of new
classes of antibiotics and vaccines
against Methicillin-resistant
Staphylococcus aureus infections.
Inventors: Michael Otto and Rong
Wang (NIAID).
Publication: R Wang et al.
Identification of novel cytolytic
peptides as key virulence determinants
for community-associated MRSA. Nat
Med. 2007. Dec;13(12):1510–1514.
Patent Status: U.S. Provisional
Application No. 60/933,573 filed 06 Jun
2007 (HHS Reference No. E–239–2007/
0–US–01); U.S. Provisional Application
E:\FR\FM\05MRN1.SGM
05MRN1
]]>Agencies
[Federal Register Volume 73, Number 44 (Wednesday, March 5, 2008)]
[Notices]
[Page 11930]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: E8-4185]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Health Resources and Services Administration
Reimbursement of Travel and Subsistence Expenses Toward Living
Organ Donation Eligibility Guidelines
AGENCY: Health Resources and Services Administration, HHS.
ACTION: Request for Comments on Proposed Changes to the Reimbursement
of Travel and Subsistence Expenses Program Eligibility Criteria.
-----------------------------------------------------------------------
SUMMARY: The Health Resources and Services Administration (HRSA)
published the final eligibility guidelines for the Reimbursement of
Travel and Subsistence Expense Program in the Federal Register on
October 5, 2007 (72 FR 57049). The purpose of this notice was to inform
the public of the eligibility requirements for participation in the
Reimbursement of Travel and Subsistence Expenses toward Living Organ
Donation Program. HRSA is requesting public comments concerning
recommended change to a specific section of the reimbursement program
eligibility guidelines.
DATES: Written comments must be submitted to the office in the address
section below by mail or e-mail on or before April 4, 2008.
ADDRESSES: Please send all written comments to James F. Burdick, M.D.,
Director, Division of Transplantation, Healthcare Systems Bureau,
Health Resources and Services Administration, Room 12C-06, Parklawn
Building, 5600 Fishers Lane, Rockville, Maryland 20857; telephone (301)
443-7577; fax (301) 594-6095; or e-mail: jburdick@hrsa.gov.
FOR FURTHER INFORMATION CONTACT: James F. Burdick, M.D., Director,
Division of Transplantation, Healthcare Systems Bureau, Health
Resources and Services Administration, Parklawn Building, Room 12C-06,
5600 Fishers Lane, Rockville, Maryland 20857; telephone (301) 443-7577;
fax (301) 594-6095; or e-mail: jburdick@hrsa.gov.
SUPPLEMENTARY INFORMATION: In its final program eligibility guidelines,
HRSA explained that ``[t]he Program will pay for a total of up to five
trips; three for the donor and two for accompanying persons. The
accompanying persons need not be the same each trip.'' (72 FR 57052).
HRSA proposes amending this paragraph to read: ``[t]he Program will pay
for a total of up to five trips; three for the donor and two for
accompanying persons. However, in cases in which the transplant center
requests the donor to return to the transplant center for additional
visits as a result of donor complications or other health related
issues, NLDAC may provide reimbursement for the additional visit(s) for
the donor and an accompanying person. The accompanying persons need not
be the same in each trip.'' The purpose of this proposed change is to
accommodate individuals who experience donor complications or other
health related issues relating to donation.
HRSA is requesting comments on this specific section.
Dated: February 26, 2008.
Elizabeth M. Duke,
Administrator.
[FR Doc. E8-4185 Filed 3-4-08; 8:45 am]
BILLING CODE 4165-15-P
